Navigation Links
Potential treatment option for severe emphysema under study
Date:9/24/2008

Emory University researchers are participating in a nationwide study to explore an investigational treatment for advanced widespread emphysema. The EASE (Exhale Airway Stents for Emphysema) Trial focuses on airway bypass, a minimally invasive procedure designed to reduce excessive lung inflation and shortness of breath typical complications of emphysema - by making new pathways for trapped air to exit the lungs.

During the airway bypass procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by several new drug-eluting stents.

"Emphysema permanently destroys lung function and there are currently limited treatment options for people with this devastating disease," says Rabih Bechara, MD, assistant professor and director of interventional pulmonology, Emory University School of Medicine. "This is an exciting study that could offer substantial relief to participants, and eventually possibly to the millions who suffer from the effects of emphysema."

Emphysema, usually caused by chronic tobacco smoking, is a persistent, progressive and irreversible lung disease characterized by shortness of breath and the destruction of lung tissue. Over time, the tiny air sacs in the lungs, or alveoli, are damaged and lose their elasticity.

This loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving emphysema sufferers with hyperinflation because they are unable to get air out of their lungs. Breathing becomes inefficient and patients have to work very hard to breathe making normal activities, such as walking, eating or even bathing, difficult. There is no cure and few treatment options are available for most patients.

"By creating new pathways for airflow with the airway bypass procedure, we hope to reduce hyperinflation and improve lung function," says Bechara, principal investigator of the study at Emory. "Currently, patients are often in poor physical condition, struggling with each breath so if we can help patients breathe easier it is likely to improve their quality of life."

Physicians commonly use bronchoscopes to examine the airways within the lungs. Participants in the trial are randomized two to one to an airway bypass or a control group. If randomized to the airway bypass group, physicians will first use a Doppler probe inserted through the bronchoscope to identify a site in the airway that is away from blood vessels. A special needle is then used to make a small opening and the stent is placed in the passageway to keep it open. The procedure involves placing up to six Exhale Drug-Eluting Stents manufactured by Broncus Technologies, Inc.

Although this procedure is still under clinical investigation, feasibility data suggest it may hold promise for patients with emphysema. Results from the open-label Exhale Drug-Eluting Stent feasibility study were published in the October 2007 issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results included a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure.


'/>"/>

Contact: Jennifer Johnson
jennifer.johnson@emory.edu
404-727-5696
Emory University
Source:Eurekalert

Related medicine news :

1. How to Help Down Syndrome and Other Special Needs Children - Free Booklet and Parenting Course Available This Month From The Institutes for the Achievement of Human Potential
2. Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease
3. A potential approach to treatment of hepatitis B virus infection
4. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
5. Measures to assess potential lung injury during ventilation inadequate
6. Malaria prevention reduces anemia and improves educational potential in Kenyan schoolchildren
7. PMC and County Announce Potential Capital Partners for Hospital
8. Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars
9. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
10. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
11. CIBC World Markets Equity Research Downgrades Target Price of BVF from $12.00 to a Staggering Low of $7.50 Based on Potential Incumbent Win in Proxy Battle
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent feature in ... Along with performing procedures, the magazine also highlights that Dr. Sadati has pioneered ... of the most common procedures he performs is his natural facelift. “As people ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The president ... DoD Military Health System but would shift more of the cost burden to military ... TRICARE-reform plan laid out in the defense budget as including limited quantifiable benefit fixes ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... Laurel, NJ (PRWEB) , ... February 11, 2016 ... ... announces the call for nominations seeking candidates for the Board of Commissioners. Individuals ... with passion, skills and experience with diversity of clinical practice settings and across ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016   ... the advancement of new health technologies, announced today " ... outstanding achievements in health tech over the past ten ... For nearly a decade, Health 2.0 has served ... and showcased and connected with thousands of technologies, companies, ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology: